[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 143.00 151.00 170.00 - 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 457

Amryt Pharma Share Discussion Threads

Showing 5251 to 5273 of 7125 messages
Chat Pages: Latest  213  212  211  210  209  208  207  206  205  204  203  202  Older
DateSubjectAuthorDiscuss
24/11/2019
13:18
I've copied these posts from another thread: spuddymadrid 24 Nov '19 - 09:25 - 10 of 12 0 0 0 hxxps://www.engineersjournal.ie/2019/11/22/seven-emerging-startups-set-to-pitch-at-final-of-ucd-2019-accelerator-programme/ spuddymadrid 24 Nov '19 - 09:28 - 11 of 12 0 0 0 2.) Branca Bunús is developing a technology to help cure Epidermolysis bullosa (EB) which affects half a million people worldwide. EB is a devastating genetic disorder that makes the skin as fragile as butterfly wings and for which there is currently no cure. Branca Bunús is developing a technology which targets the ‘wrong’ part of the diseased skin cells to correct them and help cure the disease. The Branca Bunús team includes, Professor Wenxin Wang, Dr Irene Lara Sáez, Dr Qian Xu, Dr Jonathan O’Keeffe Ahern, Dr Sigen A, UCD School of Medicine and Dr Hungyun Tai and Dr Dezhong Zhou. papillon 24 Nov '19 - 13:10 - 12 of 12 Edit 0 0 0 hTTps://www.engineersjournal.ie/2019/11/22/seven-emerging-startups-set-to-pitch-at-final-of-ucd-2019-accelerator-programme/ I think you'll find that this UCD startup, Branca Bunus, is the gene therapy that AMYT have a stake in, spuddymadrid. It was stated previously that a new company would be set up to develop the novel gene therapy. https://uk.advfn.com/stock-market/london/amryt-pharma-AMYT/share-news/Amryt-Pharma-PLC-Grant-Funding-from-Irish-Governme/78851836 "The grant has been awarded to a consortium comprised of Amryt, University College Dublin ("UCD"), Curran Scientific Limited and DEBRA Ireland. The grant funding will be matched by the consortium partners at various funding levels over the three year term of the project".
papillon
24/11/2019
13:10
hTTps://www.engineersjournal.ie/2019/11/22/seven-emerging-startups-set-to-pitch-at-final-of-ucd-2019-accelerator-programme/ I think you'll find that this UCD startup, Branca Bunus, is the gene therapy that AMYT have a stake in, spuddymadrid. It was stated previously that a new company would be set up to develop the novel gene therapy. https://uk.advfn.com/stock-market/london/amryt-pharma-AMYT/share-news/Amryt-Pharma-PLC-Grant-Funding-from-Irish-Governme/78851836 "The grant has been awarded to a consortium comprised of Amryt, University College Dublin ("UCD"), Curran Scientific Limited and DEBRA Ireland. The grant funding will be matched by the consortium partners at various funding levels over the three year term of the project".
papillon
24/11/2019
09:28
2.) Branca Bunús is developing a technology to help cure Epidermolysis bullosa (EB) which affects half a million people worldwide. EB is a devastating genetic disorder that makes the skin as fragile as butterfly wings and for which there is currently no cure. Branca Bunús is developing a technology which targets the ‘wrong’ part of the diseased skin cells to correct them and help cure the disease. The Branca Bunús team includes, Professor Wenxin Wang, Dr Irene Lara Sáez, Dr Qian Xu, Dr Jonathan O’Keeffe Ahern, Dr Sigen A, UCD School of Medicine and Dr Hungyun Tai and Dr Dezhong Zhou.
spuddymadrid
24/11/2019
09:25
hxxps://www.engineersjournal.ie/2019/11/22/seven-emerging-startups-set-to-pitch-at-final-of-ucd-2019-accelerator-programme/
spuddymadrid
21/11/2019
12:19
Where's that Nasdaq listing date? The share price needs it.
papillon
15/11/2019
19:33
"Cheers & have a splendiforous weekend!!" And let me wish the same for you, bazworth. I could do with an over £20k profit on my modest AMYT investment. Bring it on and the sooner the better! Will it happen? I can't predict share prices, but fingers crossed it does!
papillon
15/11/2019
18:48
My eyes are firmly closed! Please text a voice message to me when we get there. My meagre stipend in retirement could do with a good shove!! Cheers & have a splendiforous weekend!!
bazworth
15/11/2019
18:34
Another two 25k trades, bazworth, both @ 118p reported after the market closed at 4:35pm. Probably reporting delayed by an hour since there was no after close auction announced. The 118p price dictates they were both sells, but they could have been a rollover because the time difference between the two trades was just 13 seconds. Whatever they were that brings the number of trades today to 22. "Just wait till we’re @ £5 a share!!" When will that be, bazworth? Next week, next month, next year? Have another look into your crystal ball, bazworth, as I need more clarity! Hopefully I don't have to wait too long for that £5 per share as I'm getting on a bit! :-)
papillon
15/11/2019
17:23
Marvellous!!! Just wait till we’re @ £5 a share!!
bazworth
15/11/2019
16:49
I spoke too soon this morning! Some big volume trades this afternoon. 4 large trades totalling around 112k of shares. The biggest was for 35,650 @ 119.25p. It's shown as a sell because it's reporting was delayed by an hour. However when the trade took place (14:38:20) the quoted spread was 117p - 120p so it was a buy.
papillon
14/11/2019
21:44
It's a technicality - when considering valuation just include these shares as still being in issue. They will be reissued for no money when it suits the funds - who can't hold the shares now without breaching limits. Hence no price for the buy back.
bageo
14/11/2019
17:15
Share buyback? I don't understand,I don't see any price. https://uk.advfn.com/stock-market/london/amryt-pharma-AMYT/share-news/Amryt-Pharma-PLC-Share-Buyback/81147847
chica1
13/11/2019
16:01
O/T. Big drop in the ECO share price today following the RNS. Glad I no longer dabble in speculative AIM O&G's. I'm just gambling on an AIM listed speculative biotech, AMYT, instead!
papillon
11/11/2019
21:56
Two massive trades timed at just before 1pm, but only reported after the market closed. Both sells, but the share price responded by going up! I wonder if the trades have been worked over a number of days and have been depressing the share price and that now they have gone the share price will start to rise? These are the two trades: 400,000 @ 115.625p and timed @ 12:55:07. Proceeds £462,500,000 474,135 @ 115.50p and timed @ 12:54:15. Proceeds £547,630,000
papillon
10/11/2019
18:03
hTTps://www.thetimes.co.uk/article/agenda-mystery-rises-as-bank-of-china-goes-for-irish-broker-goodbody-cttf2090r Wiley in the right with Amryt Perhaps you should have paid attention in biology class. Joe Wiley, chief executive, and Rory Nealon, chief financial officer, were last week granted options over 10.2m shares in Amryt Pharma, an Irish drug developer. The bumper share awards have an exercise price of £1.215p each. Amryt is an orphan drug specialist, finding treatments for rare diseases. The company recently acquired Aegerion, a Canadian peer and has a drug in development to treat the skin disease epidermolysis bullosa. There are no sure things in pharma, yet Wiley has a top reputation and a nose for a deal. The rewards here could be truly massive. Wiley by name, wily by nature. brian.carey@sunday-times.ie
papillon
10/11/2019
17:19
Yep Sunday Times
alphabravo321
10/11/2019
13:07
alphabravo321, you posted the following on the lse bb today. Does ST refer to the Sunday Times? tia alphabravo321 Posts: 33 Price: 121.00 No Opinion ST Today 05:30 Wiley in the right with Amryt Perhaps you should have paid attention in biology class. Joe Wiley, chief executive, and Rory Nealon, chief financial officer, were last week granted options over 10.2m shares in Amryt Pharma, an Irish drug developer. The bumper share awards have an exercise price of £1.215p each. Amryt is an orphan drug specialist, finding treatments for rare diseases. The company recently acquired Aegerion, a Canadian peer and has a drug in development to treat the skin disease epidermolysis bullosa. There are no sure things in pharma, yet Wiley has a top reputation and a nose for a deal. The rewards here could be truly massive. Wiley by name, wily by nature.
papillon
06/11/2019
13:07
LOL, purple11. Don't forget to wake me up! "So wake me up when it's all over When I'm wiser and I'm older"
papillon
06/11/2019
11:31
nite pappy
purple11
06/11/2019
11:30
Back to sleep, until the next RNS.
papillon
05/11/2019
22:37
https://www.irishtimes.com/business/health-pharma/dublin-pharma-company-amryt-grows-sales-almost-20-1.4072998?mode=amp
tiananmen
05/11/2019
19:56
"It looks undervalued at less than 2 x full year sales. Cash helps but will get spent." Don't forget AMYT has debt, waterloo. The amount of debt must also be acknowledged in any attempt at valuing AMYT. Don't forget we've already had a broker note, waterloo. Stiffel's valuation dated 1st October. That was first posted by Bronxville on the lse bb and copied by me onto this bb last week (post 5087). Stiffel reckon … … … "that revenue-generative orphan drug companies trade at 8.8-times historic earnings." Seems rather fanciful to me, but even 4 x historic earnings valuation gives a 240p AMYT share price
papillon
05/11/2019
19:24
£zillions........! Sorry, don’t have the expertise - guess that makes me a gambler and not an investor! At least I’m a very patient gambler.... Fingers very firmly crossed!
bazworth
Chat Pages: Latest  213  212  211  210  209  208  207  206  205  204  203  202  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220122 00:46:56